Join RESTEM for an in-person and virtual R&D Day in New York to discuss the unmet needs and current treatment landscapes for autoimmune and inflammatory diseases, including idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid arthritis (RA) and facioscapulohumeral muscular dystrophy (FSHD).

The event will feature insights from leading experts:

• Guenther Koehne, MD, PhD – Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute
• Jonathan D. Krant, MD, MPH, FACP – Rheumatologist at Monadnock Community Hospital in Peterborough, New Hampshire
• Eva Chin, PhD – Executive Director of SOLVE FSHD, Former Chief Development Officer of NMD Pharma A/S
• Keith March, MD, PhD, FACC – Chief Medical Officer of RESTEM, Former Director of the University of Florida Center for Regenerative Medicine, Vice Chief of Cardiology Research, and Professor of Medicine at UF

The event will highlight RESTEM-L, a novel, off-the-shelf, investigational Umbilical lining Modified Progenitor Cells (UMPCs) therapy for a wide array of immunological and degenerative conditions. This session will explore the superior immunomodulatory profile of UMPCs and how their youthful phenotype and scalable production platform are paving the way for next-generation clinical therapies. Company management will also review selected data from RESTEM-L’s clinical trials and upcoming milestones.

A live question and answer session will follow the formal presentations.